Investor Newsletter

Issue 06 2021

MicroPort®

MicroPort® Listed Among "China's 500 Most Valuable Brands" List Again for 2021

For the second time, MicroPort Scientific Corporation (HK00853, "MicroPort®") has been listed among "China's 500 Most Valuable Brands" for 2021 with a brand value of RMB 10.365 billion. The list, together with the analysis report, was launched by the World Brand Lab in its 18th World Brand Summit 2021 which was held in Beijing on June 22, 2021, under the theme of "Sustainable Brands Drive Corporate Growth". At the Summit, Dr. Xuping Chu, former director of the Research Center of the State-owned Assets Supervision and Administration Commission of the State Council and research fellow of the China Enterprise Research Center of Tsinghua University, and Mr. Haodong Yuan, CEO of the World Executive Group and member of the expert group of the World Brand Lab, presented the trophies and certificates to the selected companies. Management experts from Harvard University, Yale University and Oxford University attended the Summit, delivered speeches online and interacted with participants on the theme of "Sustainable Branding Drive Company Growth".

World Brand Lab is a leading international institution of brand valuation and research, recognized as one of the top three global brand value assessment organizations. It was founded by Professor Robert Mundell, 1999 Nobel Laureate in Economics, who also served as the first chairman of the organization. Its "China's 500 Most Valuable Brands" list, which has been published for eighteen consecutive years, is a benchmark for demonstrating the strength of Chinese brands. Based on financial data, brand strength and consumer behavior analysis, the list measures brand value using the "present earning value method", which has become an important reference for intangible assets evaluation in the M&A process for numerous companies.

Steve Woolgar, Chairman of the World Brand Lab and Professor Emeritus of Marketing at Oxford University, stated: "Brands are the image of a country. I would like to see more people in the world learn about the story of China through Chinese brands. In the past 15 years, I have witnessed the remarkable growth of Chinese brands, some of which already possess a strong global footprint."

Firehawk® Receives Registration Approval in Venezuela

The Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®), a product of Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), has received registration approval from the Venezuelan authority Servicio Autónomo de Contraloría Sanitaria (SACS).

Firehawk® is a drug-eluting stent (DES) featuring strut in-groove coating and precision target drug-releasing patent technology. It combines the advantages of the bare metal stent and drug-eluting stent, with nearly 600 grooves evenly cut in the hair-thin but extremely hard CoCr alloy. It allows for the precise injection of drugs into the micro-grooves by means of a fully automatic 3D-printed micro-groove filling, ensuring the effectiveness of the drug whilst significantly reducing the drug loading.

Previously, products developed by Microport®, such as Firebird 2®, Foxtrot® NC and Firefighter™, have been launched in Venezuela. The registration approval of Firehawk® further enriches Microport®'s coronary product portfolio in Venezuela and expands Microport®'s global footprint of coronary products. In the future, Microport® will continue to strengthen its efforts in local markets and provide high-quality total medical solutions to patients and doctors worldwide.



MicroPort

Firehawk Liberty™ Receives Registration Approval in Colombia

Recently, the Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System ('Firehawk Liberty™'), developed by Shanghai MicroPort® Medical Group Co., Ltd. (MicroPort®), has received registration approval from the National Institute for Drug and Food Surveillance of Columbia.

Firehawk Liberty™ is a drug-eluting stent (DES) that features strut in-groove coating and precision target drug-releasing patent technology. It combines the advantages of the bare metal stent and drug-eluting stent, with nearly 600 grooves evenly cut in the hair-thin but extremely hard CoCr alloy. Firehawk Liberty™ allows for the precise injection of drugs into the micro-grooves by means of a fully automatic 3D-printed micro-groove filling, ensuring the effectiveness of the drug, whilst significantly reducing the drug loading. In addition, it features innovative stent balloon technology to optimize expansion performance, offering better crossability, traceability and pushability, thus further optimizing the vessel wall apposition.

Firehawk Liberty™ is currently approved in a number of countries and regions, including Belarus, Saudi Arabia, South Korea, Brazil, India and the European Union. In the future, MicroPort® will continue its commitment to provide more high-quality and innovative total medical solutions for patients with coronary artery diseases around the world.

MicroPort® Participates in OCC 2021 and Announces One-Year Results of Firesorb® Pivotal Study FUTURE-II

Recently, Shanghai Microport Medical (Group) Co., Ltd (MicroPort®) recently participated in the 15th Oriental Congress of Cardiology (OCC 2021) to present the key imaging and clinical results of the FUTURE-II trial – a pivotal study of the Firesorb® Bioresorbable Rapamycin Targeted Eluting Coronary Scaffold System ("Firesorb®"), a second-generation bioresorbable vascular stent system developed by MicroPort®. The results were presented by co-principal investigator, Professor Bo Xu of Fuwai Hospital of the Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases.



The FUTURE-II trial is a prospective, multicenter, non-inferiority designed randomized controlled trial, which aims to compare the safety and effectiveness of Firesorb®, the second-generation bioresorbable eluting stent, with the XIENCE cobalt-chromium everolimus-eluting stent (EES). It was carried out at 28 medical centers across China and involved 433 patients with primary obstructive coronary atherosclerotic heart disease. The one-year follow-up results show that Firesorb® is not inferior to EES based off of the primary endpoint of angiographic in-segment late lumen loss at one year and the major secondary endpoint of one-year proportion of covered struts evaluated by optical coherence tomography (OCT). Based on the results of these trials, Prof. Bo Xu recognized the performance of the Firesorb® scaffold and emphasized that the trial further demonstrated the role of the 'PSP' principle in bioresorbable stent implantation – prepare the lesion, size appropriately, and post-dilate.

In the future, with the official market approval of Firesorb®, MicroPort® will be able to provide a total medical solution for coronary artery disease, providing patients and doctors with more options for the benefit of more patients.

MicroPort

MicroPort® Orthopedics Receives "15A" ODEP Rating for its Advance® Medial-Pivot Knee System

MicroPort® Orthopedics received a "15A" rating from the Orthopedic Data Evaluation Panel (ODEP) for its independently-developed Advance® Medial-Pivot Knee System. "15A" is one of the highest clinical follow-up ratings that ODEP gives knee prosthesis products.

Established in the United Kingdom in 2002, ODEP is a global rating agency within the orthopedic industry that provides a standardized, validation rating system based on survivorship and the quality of implants throughout a long-term evaluation. At present, ODEP is one of the most authoritative and credible organizations in the field of orthopedics worldwide.

Glendy Wang, Chief Operating Officer of MicroPort®, commented, "The ODEP '15A' rating is a true testament to the superior quality and long-term stable performance of our orthopedic products. We will continue developing new technologies and innovative products based on clinical needs to provide better orthopedic solutions to patients in China and around the world. "

MicroPort

MicroPort CRM Announces European Launch of Alizea™ and Borea™ Pacemakers with Bluetooth® Connectivity and Streamlined Remote Monitoring

MicroPort CRM, a pioneering company in the field of Cardiac Rhythm management, headquartered in France with global operations, announced today the European launch of Alizea™ and Borea™ pacemakers after receiving the CE mark under the new Medical Device Regulation (MDR - 2017/745). The devices are equipped with Bluetooth®1 technology for streamlined remote monitoring when paired with the SmartView Connect™ home monitor.

Alizea™ and Borea™ pacemakers

Alizea™ and Borea™ with Bluetooth® capability have been designed without compromising on size and battery longevity. Their volume is only 11cc and the projected lifespan is 13 years with full feature set on, including remote monitoring, saving many patients from having to experience a pacemaker change. This newest generation of pacemakers also includes the more advanced features developed by MicroPort CRM, including:

- ***AutoMRI™***, which automatically protects the patient when he or she has to undergo an MRI examination, whether with a 1.5 or 3 Tesla scanner
- ***SafeR™***, a pacing mode reducing unnecessary ventricular pacing that has been proven to prevent onset of atrial fibrillation
- ***SAM™***, a Sleep Apnea Monitoring feature which reveals a largely under-diagnosed disease with significant cardiac comorbidities such as atrial fibrillation

SmartView Connect™ home monitor

"MicroPort CRM has always been committed to providing medical devices with the most advanced technology and features to improve patient outcomes and reduce the burden on the healthcare system", said Benoît Clinchamps, President of MicroPort CRM. "Alizea™ and Borea™ pacemakers, associated with SmartView Connect™ home monitor, are a perfect example of our objective to improve the management of healthcare by reducing hospital visits, while ensuring continuity of monitoring and follow-up. These new pacemakers keep patients connected to their clinical team with secured and streamlined communication."

CAPRI Clinical Investigation of ENO™/TEO™/OTO™ Pacing System by MicroPort® CRM Completes First Enrollment of Chinese Patients

Recently, the "Clinical Investigation of ENO™/TEO™/OTO™ Pacing System (CAPRI)", successfully completed the clinical enrollment of the first six patients at the Second Affiliated Hospital of Zhejiang University School of Medicine, marking the official launch of this global multicenter clinical study in China. The study, initiated by MicroPort® CRM and conducted by MicroPort Soaring CRM (Shanghai) Co., Ltd. (MSC), aims to further evaluate the safety and efficacy of the ENO™/TEO™/OTO™ Pacing System when used under 1.5T or 3.0T specific Magnetic Resonance Imaging (MRI) conditions by collecting relevant clinical evidence.

Of the six patients to receive pacemaker implantation as part of the study, five were over 50 years old and oldest was 83. The program plans to enroll 270 patients at 29 clinical centers in Europe, Australia and China with an approximately one-year follow-up. Prof. Meixiang Xiang of the Second Affiliated Hospital of Zhejiang University School of Medicine serves as the principal investigator of the study in China, and Dr. Dennis Lau of the Royal Adelaide Hospital in Australia is the Coordinating Investigator, responsible for coordinating the study across clinical centers.

Jack Zhu, General Manager of MSC, said, "MicroPort® CRM seeks to provide a total solution for patients with arrhythmias. The three pacemaker families of ENO™, TEO™ and OTO™ and the Vega pacing leads minimize unnecessary medical interventions before and after MRI examinations for patients with an implanted pacemaker, while reducing the burden on clinicians and ensuring optimal patient care. We hope that the CAPRI clinical study could lay the groundwork for the early approval of these products by the National Medical Products Administration (NMPA) of China, and provide clinicians and patients with a total solution for heart rhythm management."

MicroPort

Microport® Announces the First Patients Enrolled in the European TARGET FIRST Clinical Trial of the Firehawk™ Coronary Stent

MicroPort® CRM today announced the first enrollments in the European TARGET FIRST trial – a prospective, randomized, controlled, multi-centre clinical trial involving 2,200 patients from up to 50 clinical centers in Europe. The trial aims to evaluate that a shorter dual antiplatelet therapy, combined with the unique characteristics of the Firehawk™ stent, is a reliable option in patients with acute myocardial infarction.

The TARGET FIRST clinical trial builds on other studies in the TARGET series. The Firehawk™ stent has been extensively studied in over 2,000 patients in the comprehensive TARGET clinical program, including the most recent TARGET All Comers trial. The TARGET FIRST trial is also one of the most important series shorter dual antiplatelet therapy trials of Firehawk™ stent include TARGET SAFE, TARGET DAPT Trial.

"The launch of the TARGET FIRST clinical trial is an important milestone for MicroPort®," said Amel Amblard, VP Clinical Affairs at MicroPort CRM. "This trial will continue to enrich the clinical data already available on the Firehawk™ stent and confirms our commitment to strengthen advanced treatment options for physicians and patients".

First Implantation of Endovastec™ Minos® Stent Graft System Completed in Brazil

Minos® Abdominal Aortic Stent-Graft and Delivery System (Minos® Stent Graft System), a product developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), was recently used in Brazil for the first time. This marks the System's tenth overseas market entry, following its approval in Greece, Poland, Spain, Germany, Italy, Switzerland, Argentina, Croatia and Hungary.

The procedure, led by Dr. Victor Maia and Dr. Guilherme Meirelles of the Samaritano Paulista Hospital, involved a patient admitted to hospital with sudden onset of pain. The patient was shown to have a challenging abdominal aortic aneurysm over 5 cm in diameter, involving the superior mesenteric artery with a very tortuous iliac artery hindering access. The surgical team selected the Minos® Stent Graft System for placement across the superior mesenteric artery and used the chimney technique to reconstruct the superior mesenteric artery and the left and right renal arteries. Postoperative angiography showed an effectively isolated aneurysm, and the stent graft was well conformed to the patient's anatomy, allowing for the restoration of blood flow in the branch stent, indicating a successful operation.

Zhenghua Miao, President of Endovastec™, said, "Since it entered overseas markets, the Minos® Stent Graft System has shown excellent performance in clinical practice in a number of countries in Europe and South America. It is receiving recognition by experts for providing a better solution for patients with complex abdominal aortic anatomical patterns. As we continue to make our products available in new markets, Endovastec™ will further enhance in-depth cooperation with overseas clinical experts, striving to promote more high-quality and innovative solutions for the treatment of aortic and peripheral vascular diseases in overseas markets, so as to benefit more patients worldwide. "



MicroPort

MicroPort® MedBot DFVision® 3D Electronic Laparoscope Approved for Marketing by NMPA

On June 8, 2021, MicroPort MedBot (Shanghai) Co., Ltd. ('MicroPort® MedBot') received a registration certificate issued by China's National Medical Products Administration (NMPA) for its DFVision® three-dimensional electronic laparoscope ('DFVision®'). The registration certificate, which followed the product's entry into NMPA's special approval process for innovative medical devices in 2019, is the first product marketing approval received by MicroPort® MedBot.

The DFVision® is designed for use in clinical practices such as thoracic, general surgery, gynecology and urology departments. During the research and development phase, MicroPort® MedBot placed great emphasis on practical clinical needs. In comparison with conventional two-dimensional laparoscopes, DFVision® enables a three-dimensional vision of the surgical field of view and depth perception for surgical operations through dual-channel image capturing, which helps surgeons to perform fast and sophisticated directional maneuvers, including suturing, anastomosis and functional reconstruction, as well as hand changing and knot tying with needle holders.

Relying on the proprietary design that combines high-resolution objectives lens and an electronic microscope, DFVision® enables the full HD presentation of dual-channel images without the need for bulky optical components of conventional laparoscopes. This significantly reduces the weight, alleviating the fatigue of the user, which in turn leads to more stable intraoperative images. DFVision® offers a high-level of stereoscopic vision closer to reality, allowing the surgeon to identify fine tissues based on high-definition images of organ structure, while greatly improving the surgical experience and flattening the learning curve for surgeons who lack experience in laparoscopic surgery.

Dr. Chao He, President of MicroPort® MedBot, said, "DFVision® is the first product approved for marketing in the laparoscopic field, one of the 'five tracks' of MicroPort® MedBot portfolio, marking our presence at the forefront of the 3D electronic laparoscopy market. The launch of DFVision® will not only bring a more comprehensive solution for laparoscopic surgeries but also promote the development of the related industry chain in China and further reduce the medical and economic burden of patients. In the future, we will continue to innovate and provide patients and physicians in China and around the world with a total surgical solutions based on intelligent robotics that can prolong and reshape lives. "



MicroPort® EP IceMagic® Cardiac Cryoablation System Enters "Green Path"

On June 8, the IceMagic® Cardiac Cryoablation System, developed by Shanghai MicroPort® EP MedTech Co., Ltd. (MicroPort® EP), was granted access to the "Green Path", a special review process for innovative medical devices by China's National Medical Products Administration (NMPA). This marks the 21st product from a MicroPort® subsidiary or related company that is eligible for the "Green Path" procedure.

The main treatment options for atrial fibrillation include medication therapy and non-medication therapy. The Green Path-ready IceMagic® Cardiac Cryoablation System applies a number of core invention patents in R&D. It consists of a cryoablation device, cryoballoon catheters, a disposable intracardiac mapping catheter and a steerable introducer set. In May 2020, the system successfully completed the first pre-market clinical trial enrollment, and its effect was fully affirmed by the physician team.

Dr. Yiyong Sun, President of MicroPort® EP, said, "IceMagic® Cardiac cryoablation system for the treatment of atrial fibrillation has been widely used and recognized, but it is still in a foreign monopoly stage, and there has been an absence of such devices in China. We are committed to developing equivalent products with independent intellectual property rights to promote the development and usage of this technology domestically, as a means to support patients and doctors with more affordable solutions. The inclusion of the IceMagic® Cardiac Cryoablation System into the Green Path is a recognition of the R&D and innovative capability of MicroPort® EP."

MicroPort® EP Successfully Performs First Procedure in Belgium

A team of electrophysiologists in Belgium have successfully completed an electrophysiology (EP) procedure for atrioventricular node reentrant tachycardia using a full range of products developed by Shanghai MicroPort® EP MedTech Co., Ltd. (MicroPort® EP). The products used during the procedure, which marked the first 3D case for MicroPort® EP in the Belgian market, included Columbus 3D EP Navigation System (Columbus®), OptimAblate® Cardiac RF Generator, OptimAblate® Irrigation Pump, and FireMagic® 3D Saline Irrigated RF Ablation Catheter, along with other accessories.

To date, over 20,000 procedures have been performed worldwide using Columbus®, and the products and services of MicroPort® EP are available in more than 20 countries in Europe, Oceania, Africa, South America and Asia. Recently, MicroPort® EP successfully entered into the Brazilian market, with team of local experts applying Columbus® and its ancillary catheter to successfully complete the 3D ablation cases. In future, MicroPort® EP will continue to focus on innovation and development, offering world-class total medical solutions for electrophysiological interventions so that more patients enjoy a healthy life.

Dr. Yiyong Sun, President of MicroPort® EP, said, "As the population is aging across the world, the incidence of cardiac arrhythmias is also on the rise. In an effort to bring premium products and services to more patients with heart arrhythmia and doctors worldwide, MicroPort® EP is speeding up its presence in the global market."

Investor Newsletter

Issue 06 2021

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com